Paper39401495
Immunotherapy-Based Strategies for Treatment of Type 1 Diabetes.
Jacobsen LM and 1 other. Horm Res Paediatr, 2025. Cited by 4 papers, by iCite.
Cite this record
ConductScience Library. Immunotherapy-Based Strategies for Treatment of Type 1 Diabetes. Papers, record 39401495. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39401495
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics6
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Diabetes Mellitus, Type 1 | Major topic |
| Immunotherapy | Major topic |
| Antibodies, Monoclonal, Humanized | Major topic |
| Humans | |
| Adolescent | |
| Insulin |
Source PubMed
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| K08 DK128628 | NIDDK NIH HHS | United States | K08DK128628 | PubMed and NIH | NIH RePORTER |
| P01 AI042288 | NIAID NIH HHS | United States | P01AI042288 | PubMed and NIH | NIH RePORTER |
References51
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 18779574 | IL-21 signaling is critical for the development of type I diabetes in the NOD mouse. | Proc Natl Acad Sci U S A | 2008 | https://conductscience.org/library/papers/18779574 | PubMed |
| 2 | 33662334 | Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial. | Lancet Diabetes Endocrinol | 2021 | https://conductscience.org/library/papers/33662334 | PubMed |
| 3 | 21714999 | Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial. | Lancet | 2011 | https://conductscience.org/library/papers/21714999 | PubMed |
| 4 | 23562090 | Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials. | Lancet | 2013 | https://conductscience.org/library/papers/23562090 | PubMed |
| 5 | 24026563 | B-lymphocyte depletion with rituximab and β-cell function: two-year results. | Diabetes Care | 2014 | https://conductscience.org/library/papers/24026563 | PubMed |
| 6 | 14693724 | C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001. | Diabetes | 2004 | https://conductscience.org/library/papers/14693724 | PubMed |
| 7 | 29925930 | Elevated T cell levels in peripheral blood predict poor clinical response following rituximab treatment in new-onset type 1 diabetes. | Genes Immun | 2019 | https://conductscience.org/library/papers/29925930 | PubMed |
| 8 | 19940299 | Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. | N Engl J Med | 2009 | https://conductscience.org/library/papers/19940299 | PubMed |
| 9 | 36566274 | A randomized trial of oral gamma aminobutyric acid (GABA) or the combination of GABA with glutamic acid decarboxylase (GAD) on pancreatic islet endocrine function in children with newly diagnosed type 1 diabetes. | Nat Commun | 2022 | https://conductscience.org/library/papers/36566274 | PubMed |
| 10 | 38055252 | Baricitinib and β-Cell Function in Patients with New-Onset Type 1 Diabetes. | N Engl J Med | 2023 | https://conductscience.org/library/papers/38055252 | PubMed |
| 11 | 24089509 | Impact of C-peptide preservation on metabolic and clinical outcomes in the Diabetes Control and Complications Trial. | Diabetes | 2014 | https://conductscience.org/library/papers/24089509 | PubMed |
| 12 | 31180194 | An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes. | N Engl J Med | 2019 | https://conductscience.org/library/papers/31180194 | PubMed |
| 13 | 33469446 | New Insights Into the Role of Autoreactive CD8 T Cells and Cytokines in Human Type 1 Diabetes. | Front Endocrinol (Lausanne) | 2020 | https://conductscience.org/library/papers/33469446 | PubMed |
| 14 | 15855569 | Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial--Type 1. | Diabetes Care | 2005 | https://conductscience.org/library/papers/15855569 | PubMed |
| 15 | 37861217 | Teplizumab and β-Cell Function in Newly Diagnosed Type 1 Diabetes. | N Engl J Med | 2023 | https://conductscience.org/library/papers/37861217 | PubMed |
| 16 | 30967424 | Low-Dose Anti-Thymocyte Globulin Preserves C-Peptide, Reduces HbA1c, and Increases Regulatory to Conventional T-Cell Ratios in New-Onset Type 1 Diabetes: Two-Year Clinical Trial Data. | Diabetes | 2019 | https://conductscience.org/library/papers/30967424 | PubMed |
| 17 | 32704564 | A quantitative measure of treatment response in recent-onset type 1 diabetes. | Endocrinol Diabetes Metab | 2020 | https://conductscience.org/library/papers/32704564 | PubMed |
| 18 | 39079992 | Ustekinumab for type 1 diabetes in adolescents: a multicenter, double-blind, randomized phase 2 trial. | Nat Med | 2024 | https://conductscience.org/library/papers/39079992 | PubMed |
| 19 | 24296850 | Costimulation modulation with abatacept in patients with recent-onset type 1 diabetes: follow-up 1 year after cessation of treatment. | Diabetes Care | 2014 | https://conductscience.org/library/papers/24296850 | PubMed |
| 20 | 30012675 | Low-Dose Anti-Thymocyte Globulin (ATG) Preserves β-Cell Function and Improves HbA1c in New-Onset Type 1 Diabetes. | Diabetes Care | 2018 | https://conductscience.org/library/papers/30012675 | PubMed |
Cited by4
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 4 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42851930 | Artificial intelligence-driven therapeutics for disease modification in type 1 diabetes: a digital public health and clinical translation framework. | Front Public Health | 2026 | https://conductscience.org/library/papers/42851930 | PubMed |
| 42589969 | Reducing Diabetic Ketoacidosis in Pediatric Type 1 Diabetes: The Impact of Screening Programs and Early Disease-Modifying Treatment. | J Clin Med | 2026 | https://conductscience.org/library/papers/42589969 | PubMed |
| 41007060 | Advances in Childhood Diabetes. | Children (Basel) | 2025 | https://conductscience.org/library/papers/41007060 | PubMed |
| 39606229 | Small-molecule inhibitors of the CD40-CD40L costimulatory interaction are effective in pancreatic islet transplantation and prevention of type 1 diabetes models. | Front Immunol | 2024 | https://conductscience.org/library/papers/39606229 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| INS | 3630 | PubTator's text mining | https://conductscience.org/library/genes/3630 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39401495
GET https://conductscience.org/api/papers/v1/39401495/references?page=2